Government plans to offer support for treatment of rare diseases

"Accordingly, as these patients have already commenced treatment, Sarepta Therapeutics has committed, as per the communication received by the NDRC (National Rare Diseases' Committee), to continue treating these patients with Duchenne muscular dystrophy for the next three months, and to supply the medication free of cost during this period," it said. The court directed doctor Madhulika Kabra from the All India Institute of Medical Science to place the order for the medicine with the company within one week and expedite the procurement for these 14 patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IlUuKkT
via IFTTT